Review
Cell Biology
Jade Hawksworth, Esperanza Fernandez, Kris Gevaert
Summary: Alzheimer's disease, the most common form of dementia, lacks effective treatments and early diagnostic tools. Proteomic technologies have identified potential biomarkers for AD, and studies have focused on amyloid and tau proteins as well as proteins associated with neurodegeneration, neuroinflammation, lipid transport, and mitochondrial dysfunction.
AGEING RESEARCH REVIEWS
(2022)
Article
Biochemistry & Molecular Biology
Marina Arcaro, Chiara Fenoglio, Maria Serpente, Andrea Arighi, Giorgio G. Fumagalli, Luca Sacchi, Stefano Floro, Marianna D'Anca, Federica Sorrentino, Caterina Visconte, Alberto Perego, Elio Scarpini, Daniela Galimberti
Summary: This study compared the application of ELISA and CLEIA methods for detecting cerebrospinal fluid biomarkers. The results demonstrated that CLEIA method had higher accuracy and better automation, which could potentially be useful in clinical diagnosis and studies.
Article
Clinical Neurology
Argonde C. van Harten, Heather J. Wiste, Stephen D. Weigand, Michelle M. Mielke, Walter K. Kremers, Udo Eichenlaub, Roy B. Dyer, Alicia Algeciras-Schimnich, David S. Knopman, Clifford R. Jack Jr, Ronald C. Petersen
Summary: CSF t-tau/A beta 42 and p-tau/A beta 42 ratios are robust indicators of AD with higher agreement with amyloid PET scans. Individual biomarkers have worse diagnostic properties and more variable results in terms of positive and negative percent agreement.
ALZHEIMERS & DEMENTIA
(2022)
Article
Medicine, General & Internal
Helena Sophia Gleerup, Camilla Steen Jensen, Peter Hogh, Steen Gregers Hasselbalch, Anja Hviid Simonsen
Summary: This study evaluated the levels of lactoferrin in cerebrospinal fluid (CSF) and saliva in a cohort of patients with neurodegenerative dementias, finding that lactoferrin could not differentiate between diagnostic groups. Additionally, no significant relationships were found between lactoferrin levels and tau, phosphorylated tau (p-tau), and amyloid 1-42 (A beta(42)) in CSF.
Article
Geriatrics & Gerontology
Daniel A. Llano, Priya Devanarayan, Viswanath Devanarayan
Summary: This study proposes a framework for classifying and combining biomarkers for Alzheimer's Disease (AD). The researchers found that low levels of VGF in cerebrospinal fluid (CSF) can serve as a strong predictor for the conversion from mild cognitive impairment (MCI) to AD.
NEUROBIOLOGY OF AGING
(2023)
Article
Biochemistry & Molecular Biology
Chiara Giuseppina Bonomi, Agostino Chiaravalloti, Riccardo Camedda, Francesco Ricci, Nicola Biagio Mercuri, Orazio Schillaci, Giacomo Koch, Alessandro Martorana, Caterina Motta
Summary: The study investigates the association between markers of microglial and astrocytic activity and glucose uptake in patients with Alzheimer's Disease. The results suggest that there is a correlation between markers of astrogliosis and cortical glucose uptake in symptomatic sporadic AD, indicating the role of astrocytes in shaping regional hypometabolism and clinical presentation.
Article
Multidisciplinary Sciences
Timo Eninger, Stephan A. Mueller, Mehtap Bacioglu, Manuel Schweighauser, Marius Lambert, Luis F. Maia, Jonas J. Neher, Sarah M. Hornfeck, Ulrike Obermueller, Gernot Kleinberger, Christian Haass, Philipp J. Kahle, Matthias Staufenbiel, Lingyan Ping, Duc M. Duong, Allan Levey, Nicholas T. Seyfried, Stefan F. Lichtenthaler, Mathias Jucker, Stephan A. Kaeser
Summary: Single-cell transcriptomics has revealed glial activation states associated with neurodegenerative diseases, but little is known about biomarker changes in bodily fluids. This study explored proteomic changes in cerebrospinal fluid related to proteopathic lesions in mouse models and found increased glial-derived proteins that could also be detected in human cerebrospinal fluid, supporting efforts to identify fluid biomarkers for neurodegenerative diseases.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Clinical Neurology
Lei Liu, Bianca M. Lauro, Amy He, Hyo Lee, Sanjay Bhattarai, Michael S. Wolfe, David A. Bennett, Celeste M. Karch, Tracy Young-Pearse, Dennis J. Selkoe
Summary: This study aims to identify biomarkers for Alzheimer's disease (AD) and finds that the A beta 37/42 ratio can be used to distinguish AD from normal aging. Experimental results show that this ratio outperforms the traditional ratio in differentiating physiological and pathological states in cell culture, brain tissue, and cerebrospinal fluid. The findings may provide a new indicator for early diagnosis of AD.
ALZHEIMERS & DEMENTIA
(2023)
Article
Biochemistry & Molecular Biology
Barbara Avelar-Pereira, Michael E. Belloy, Ruth O'Hara, S. M. Hadi Hosseini
Summary: This study utilizes a multi-dimensional network framework for the detection and analysis of Alzheimer's disease (AD). The results show that multilayer community detection accurately identifies AD and can identify clinically misdiagnosed cases. Additionally, this method can identify subtypes with similar multidisciplinary profiles, providing unique insight into the heterogeneity of AD.
MOLECULAR PSYCHIATRY
(2023)
Article
Medicine, Research & Experimental
Juan Lantero-Rodriguez, Anniina Snellman, Andrea L. Benedet, Marta Mila-Aloma, Elena Camporesi, Laia Montoliu-Gaya, Nicholas J. Ashton, Agathe Vrillon, Thomas K. Karikari, Juan Domingo Gispert, Gemma Salvado, Mahnaz Shekari, Christina E. Toomey, Tammaryn L. Lashley, Henrik Zetterberg, Marc Suarez-Calvet, Gunnar Brinkmalm, Pedro Rosa Neto, Kaj Blennow
Summary: Alzheimer's disease has a long preclinical phase and requires biomarkers for early pathological changes. P-tau235 may be a key feature and staging biomarker. A new CSF p-tau235 assay shows promise in clinical research.
EMBO MOLECULAR MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Zhonghong Yan, Guanran Wang, Xingyang Shi
Summary: Chronic kidney disease (CKD) poses a serious public health concern globally, with issues including inaccurate diagnosis, dependency on biopsies, and multifactorial prognosis challenges in clinical treatment and management. Developing effective biomarkers is crucial for improving CKD prognosis and clinical management.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Kanta Horie, Nicolas R. Barthelemy, Chihiro Sato, Randall J. Bateman
Summary: The study analyzed MTBR-tau species in CSF and found that tau species containing the upstream region of MTBR were highly correlated with tau PET and cognitive assessments in Alzheimer's disease, suggesting they could serve as biomarkers for staging Alzheimer's disease and tracking tau-directed therapeutics development.
Article
Clinical Neurology
Kanta Horie, Nicolas R. Barthelemy, Chihiro Sato, Randall J. Bateman
Summary: The study analyzed MTBR-Tau species in Alzheimer's disease and control CSF using sequential immunoprecipitation and chemical extraction methods followed by mass spectrometry. The species containing the region beginning at residue 243 were found to be highly correlated with tau PET and cognitive measures. This suggests that CSF level of tau species containing the upstream region of MTBR may serve as biomarkers to stage Alzheimer's disease and track the development of tau-directed therapeutics.
Article
Neurosciences
Jodi Maple-Grodem, Anastasia Ushakova, Kenn Freddy Pedersen, Ole-Bjorn Tysnes, Guido Alves, Johannes Lange
Summary: This study used multiple biomarkers to measure protein levels in cerebrospinal fluid of newly diagnosed PD patients and controls, and found four proteins to be downregulated in PD patients. Additionally, higher levels of tau protein were associated with faster cognitive decline after PD diagnosis.
NEUROBIOLOGY OF DISEASE
(2023)
Article
Oncology
Mai M. Abdelmoaty, Jatin Machhi, Pravin Yeapuri, Farah Shahjin, Vikas Kumar, Katherine E. Olson, R. Lee Mosley, Howard E. Gendelman
Summary: This study investigates the gene and protein expression changes in monocytes before and during treatment in Parkinson's disease (PD) patients. The results show that monocytes may serve as early biomarkers for tracking immune-based interventions in PD, providing new insights for treatment and research.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)